Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial
(LTPH) DALLAS--(BUSINESS WIRE)--Type C Meeting for LP-184/STAR-001
Related Questions
How will the clarified regulatory pathway affect the timeline and likelihood of FDA approval for the pediatric CNS cancer trial?
What potential market upside or downside could this development create for Lantern Pharma's stock and its valuation?
How does this Type C meeting outcome compare to similar pediatric oncology programs at competing biotech firms?